Expertise in
8
conditions

Eric W. Van Den Neste

Brussels, BRU, BE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Brussels, BRU, BE 

Overview

Eric Van Den Neste practices practicing medicine in Brussels, Belgium.

Mr. Van Den Neste is highly rated in 8 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 80 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Brussels, BRU 1000, Belgium
Other Locations
CHU UCL Namur, Godinne site, UCLouvain
Namur, WAL, Belgium
Leuven, VLG, Belgium
Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, Saint-lambert, WAL 1200, Belgium
Yvoir, WAL, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas
A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas
Enrollment Status: Terminated
Publish Date: October 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

80 Total Publications

Prognostic value of a simple distance index derived from PET maximum intensity projection.
Prognostic value of a simple distance index derived from PET maximum intensity projection.
Journal: Frontiers in medicine
Published: January 23, 2025

Frequently Asked Questions about Eric W. Van Den Neste

Is Eric W. Van Den Neste a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Eric W. Van Den Neste is classified as an Distinguished expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eric W. Van Den Neste participate in research or clinical trials?

Yes. Eric W. Van Den Neste has published 80 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Eric W. Van Den Neste's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Den Neste's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile